F S&P 500
5,436.50 -1.00 (-0.02%) F Dow Jones
38,604.00 -1.00 (-0.00%) F Nasdaq
19,694.00 +8.50 (+0.04%) E-mini Russell 2000 Index Futur
2,008.80 +0.80 (+0.04%) Petróleo
78.11 -0.34 (-0.43%) Oro
2,333.50 -15.60 (-0.66%)
Obio Technology (Shanghai) Corp., Ltd. (688238.SS)
Obio Technology (Shanghai) Corp., Ltd.
Building 19
Lane 908, Ziping Road International Medical Park Pudong New Area
Shanghai 201321
China
86 21 5858 5887
https://www.obiosh.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 731
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Oudong Pan | Founder & Chairman of the Board | N/D | N/D | 1968 |
| Mr. Guodong Jia Ph.D. | GM & Director | N/D | N/D | 1981 |
| Mr. Junyi Pan | Investment Director & Director | N/D | N/D | 1994 |
| Ms. Qingmei Xia | Vice President of Human Resources & Commercial Management | N/D | N/D | 1979 |
| Mr. Fujie Wang | VP of Supply Chain & Information Technology and Director | N/D | N/D | 1975 |
| Ms. Shan Yin | Deputy GM & Director | N/D | N/D | 1982 |
| Mr. Xinglin Yang | R & D Director | N/D | N/D | 1976 |
| Ms. Luyuan Xu | Deputy GM, CFO & Board Secretary | N/D | N/D | 1970 |
| Qinbin Wu | Chief Quality Officer | N/D | N/D | N/D |
Descripción
Obio Technology (Shanghai) Corp., Ltd., a biotechnology company, focuses on the development of gene therapy vectors in China. The company provides gene function and gene therapy research, and other CRO services, such as drug target and drug efficacy research. It also offers CDMO services, such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs. The company was founded in 2013 and is headquartered in Shanghai, China.
Gestión corporativa
La calificación ISS Governance QuickScore de Obio Technology (Shanghai) Corp., Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
